3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Acrocephalosyndactylia
6
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Myeloproliferative Disorders
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Stomach Neoplasms
1
Solid Tumor
1
Recurrence
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Eosinophilia
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Malignancies
1
Interventions
Temozolomide
4
Flucytosine
4
vocimagene amiretrorepvec
3
vorasidenib
2
trametinib
2
paclitaxel-Angiopep-2 conjugate
2
dabrafenib
2
Surgical Procedures, Operative
2
OKN 007
2
Chlorotoxin
2
Carmustine
2
talampanel
1
selinexor
1
pemigatinib
1
pembrolizumab
1
olutasidenib
1
motexafin gadolinium
1
exatecan
1
Vincristine
1
Radiation
1
PF-06840003
1
ONC206
1
O(6)-benzylguanine
1
Metabolism
1
IL13-PE38
1
Genetic Therapy
1
Genetic Engineering
1
Filgrastim
1
Fentanyl
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Oligodendroglioma
×
pemigatinib
×
Clear all
NCT05267106
2025-12-30
FIGHT-209
Incyte Corporation
Phase 2
Terminated
83 enrolled
18 charts